Ginger Nicol

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/394176/publications.pdf

Version: 2024-02-01

567281 377865 1,339 44 15 34 citations h-index g-index papers 48 48 48 2273 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effectiveness of theory-based digital self-management interventions for improving depression, anxiety, fatigue and self-efficacy in people with neurological disorders: A systematic review and meta-analysis. Journal of Telemedicine and Telecare, 2022, 28, 547-558.	2.7	23
2	Improving Beverage Choice in Adults with Developmental Disabilities: Implementation of a Token Reinforcement System in a Community Residential Setting. Journal of Autism and Developmental Disorders, 2022, 52, 1523-1535.	2.7	1
3	Academic-Community Partnership to Improve Pediatric Mental Health Access: Missouri Child Psychiatry Access Project. Psychiatric Services, 2022, 73, 588-591.	2.0	6
4	Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors: Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and Alzheimer's Disease Prevention. Pharmacopsychiatry, 2022, 55, 24-29.	3.3	14
5	Effectiveness of non-pharmacological interventions for treating post-stroke depressive symptoms: Systematic review and meta-analysis of randomized controlled trials. Topics in Stroke Rehabilitation, 2021, 28, 289-320.	1.9	8
6	Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression. Psychopharmacology, 2021, 238, 1157-1169.	3.1	9
7	Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression. Journal of Clinical Psychopharmacology, 2021, 41, 31-35.	1.4	7
8	Getting to Precision Psychopharmacology in Child Psychiatry: The Value of Adverse Treatment Effects. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 1-3.	1.3	2
9	Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders. Journal of Psychiatry and Neuroscience, 2021, 46, E97-E110.	2.4	19
10	Going remote: Implementing digital research methods at an academic medical center during COVID-19. Journal of Clinical and Translational Science, 2021, 5, e189.	0.6	7
11	Mindfulness, Education, and Exercise for age-related cognitive decline: Study protocol, pilot study results, and description of the baseline sample. Clinical Trials, 2020, 17, 581-594.	1.6	13
12	Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 2292.	7.4	421
13	Action at a Distance: Geriatric Research during a Pandemic. Journal of the American Geriatrics Society, 2020, 68, 922-925.	2.6	91
14	A Framework for Advancing Precision Medicine in Clinical Trials for Mental Disorders. JAMA Psychiatry, 2020, 77, 663.	11.0	36
15	Does patient expectancy account for the cognitive and clinical benefits of mindfulness training in older adults?. International Journal of Geriatric Psychiatry, 2020, 35, 626-632.	2.7	8
16	A Smartphone-Based Technique to Detect Dynamic User Preferences for Tailoring Behavioral Interventions: Observational Utility Study of Ecological Daily Needs Assessment. JMIR MHealth and UHealth, 2020, 8, e18609.	3.7	8
17	"What Were You Before the War?―Repurposing Psychiatry During the COVID-19 Pandemic. Journal of Clinical Psychiatry, 2020, 81, .	2.2	31
18	Comorbid anxiety in lateâ€life depression: Relationship with remission and suicidal ideation on venlafaxine treatment. Depression and Anxiety, 2019, 36, 1125-1134.	4.1	31

#	Article	IF	CITATIONS
19	S80. FACTORS IMPACTING RESPONSE TO AN INTERACTIVE OBESITY TREATMENT APPROACH (IOTA) ADAPTED FOR USE IN INDIVIDUALS WITH SEVERE MENTAL ILLNESS (SMI). Schizophrenia Bulletin, 2019, 45, S337-S338.	4.3	3
20	Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 439-447.	1.3	10
21	Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole. Journal of Psychiatric Research, 2019, 114, 67-74.	3.1	3
22	When All Else Fails, Listen to the Patient: A Viewpoint on the Use of Ecological Momentary Assessment in Clinical Trials. JMIR Mental Health, 2019, 6, e11845.	3.3	26
23	Building a Bridge Between Genetics and Outcomes Research: Application in Autism (The AutGO Study). Patient, 2018, 11, 451-462.	2.7	3
24	Cognitive Improvement in Older Adults in the Year After Hip Fracture: Implications for Brain Resilience in Advanced Aging. American Journal of Geriatric Psychiatry, 2018, 26, 1119-1127.	1.2	7
25	Assessment and Treatment of Pediatric Sleep Problems: Knowledge, Skills, Attitudes and Practices in a Group of Community Child Psychiatrists. Medical Sciences (Basel, Switzerland), 2018, 6, 18.	2.9	1
26	Gestational Diabetes Risk During Treatment With Antipsychotic Medications. American Journal of Psychiatry, 2018, 175, 498-499.	7.2	0
27	Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths. JAMA Psychiatry, 2018, 75, 788.	11.0	54
28	The Prevalence of Past 12â€Month and Lifetime <scp>DSMâ€IV</scp> Eating Disorders by <scp>BMI</scp> Category in <scp>US</scp> Men and Women. European Eating Disorders Review, 2017, 25, 165-171.	4.1	102
29	Effect of Metabolic Syndrome on Lateâ€Life Depression: Associations with Disease Severity and Treatment Resistance. Journal of the American Geriatrics Society, 2017, 65, 2651-2658.	2.6	27
30	Getting to More Effective Weight Management in Antipsychotic-Treated Youth: A Survey of Barriers and Preferences. Childhood Obesity, 2016, 12, 70-76.	1.5	16
31	Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 415-423.	0.5	61
32	The Role of Clinical Setting and Management Approach in Metabolic Testing Among Youths and Adults Treated With Antipsychotics. Psychiatric Services, 2016, 67, 128-132.	2.0	10
33	Behavioral Weight Loss Treatment for Youth Treated With Antipsychotic Medications. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, 2016, 4, 96-104.	0.6	11
34	Psychotropic Drug Use Among Preschool Children in the Medicaid Program From 36 States. American Journal of Public Health, 2015, 105, 524-529.	2.7	29
35	Adiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3418-3426.	3.6	2

3

#	Article	IF	CITATION
37	Correlates of weight gain during long-term risperidone treatment in children and adolescents. Child and Adolescent Psychiatry and Mental Health, 2012, 6, 21.	2.5	12
38	Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Frontiers in Psychiatry, 2012, 3, 62.	2.6	25
39	Implementation of a Glucose Screening Program Based on Diffusion of Innovation Theory Methods. Psychiatric Services, 2011, 62, 12-14.	2.0	10
40	Metabolic Screening in Children Receiving Antipsychotic Drug Treatment. JAMA Pediatrics, 2010, 164, 344-51.	3.0	136
41	Treating Comorbid Anxiety and Aggression in Children. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 833.	0.5	5
42	Review: Children and adolescents with schizophrenia spectrum disorders respond to antipsychotics, but are susceptible to adverse events. Evidence-Based Mental Health, 2008, 11, 81-81.	4.5	3
43	Cardinal Symptoms of Mania in Clinically Referred Preschoolers: Description of Three Clinical Cases with Presumptive Preschool Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 237-244.	1.3	14
44	Using Innovation-Corps (I-Corpsâ,,¢) Methods to Adapt a Mobile Health (mHealth) Obesity Treatment for Community Mental Health Settings. Frontiers in Digital Health, 0, 4, .	2.8	4